Tejara Capital Ltd Takes $2.27 Million Position in QuidelOrtho Corporation $QDEL
Tejara Capital Ltd has acquired a new stake in QuidelOrtho Corporation (NASDAQ:QDEL) worth approximately $2.27 million, representing about 0.19% of the company. Despite this investment and QuidelOrtho beating recent quarterly earnings and revenue estimates, analyst sentiment remains cautious with a consensus rating of "Reduce" and an average price target of $13.62. Other institutional investors like T. Rowe Price Investment Management Inc. and BlackRock Inc. also hold significant stakes, with institutional investors collectively owning 99% of the stock.
Rice Hall James & Associates LLC Invests $18.63 Million in QuidelOrtho Corporation $QDEL
Rice Hall James & Associates LLC has acquired a new stake in QuidelOrtho Corporation (NASDAQ:QDEL) worth approximately $18.63 million, representing 1.56% of the company. Other institutional investors have also adjusted their holdings in QuidelOrtho, with institutional ownership nearing 99%. Despite beating earnings expectations, the company faces a "Reduce" consensus rating from analysts, with a target price below its opening stock price.
QuidelOrtho (QDEL) Is Up 6.0% After Cutting 2026 Revenue Outlook Amid Narrowing Losses – What's Changed
QuidelOrtho (QDEL) saw its stock rise by 6.0% despite cutting its 2026 revenue guidance to US$2.52–2.60 billion from US$2.70–2.75 billion. The company reported narrower losses in Q2 2026, with sales of US$630.9 million, but faces ongoing challenges including persistent losses and a tight cash position. The new CFO, Micah Young, will oversee cost control and portfolio decisions as investors monitor the company's path to profitability by 2029.
QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?
QuidelOrtho (QDEL) has seen its stock rally 31.7% in three months due to resilient core diagnostics growth and cost-saving initiatives. However, the company faces headwinds from a sharp slowdown in China, weakening respiratory demand, and a cut in its 2026 revenue and earnings guidance, along with a heavily leveraged balance sheet. The stock currently holds a Zacks Rank #5 (Strong Sell), indicating potential challenges in sustaining its recent gains.
Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?
QuidelOrtho Corporation (QDEL) is facing challenges due to weakening demand in China and uncertain respiratory product demand, which are offsetting resilience in its core diagnostics businesses. Despite cost-saving efforts and the acquisition of LEX Diagnostics to boost its molecular strategy with NULEXA, the company's financial position is strained by weak cash conversion and high leverage. Consequently, Zacks Investment Research has assigned QDEL a "Strong Sell" rating, suggesting a cautious investment approach until operational improvements lead to stronger financial performance.
QuidelOrtho (NASDAQ:QDEL) Stock Rating Lowered by Zacks Research
Zacks Research has downgraded QuidelOrtho (NASDAQ:QDEL) from a "hold" to a "strong sell" rating, contributing to a broader consensus "Reduce" rating and an average price target of $13.62. Despite the downgrade, QuidelOrtho shares were up 1.8% at market open, trading at $15.09, and the company recently exceeded quarterly earnings expectations with $0.13 EPS against a projected loss of $0.05. Institutional investors hold approximately 99% of the company's shares.
Invesco Ltd. (QDEL holder) reports 5.1% beneficial stake in QuidelOrtho Corp
Invesco Ltd. has filed a SCHEDULE 13G report disclosing a 5.1% beneficial ownership stake in QuidelOrtho Corp (QDEL). The filing indicates that Invesco Ltd., acting as a parent holding company for its investment advisers, beneficially owns 3,473,432 shares of common stock. While Invesco has sole voting and dispositive power over these shares, the economic interest ultimately belongs to its clients, with no single client holding more than 5% economic ownership.
QuidelOrtho (QDEL) Is Down 7.5% After Cutting 2026 Revenue Outlook Amid Softer COVID Testing Demand
QuidelOrtho (QDEL) shares fell 7.5% after the company cut its full-year 2026 revenue outlook to between US$2.52 billion and US$2.60 billion, down from US$2.70 billion to US$2.75 billion. This reduction reflects softer first-half sales, ongoing pressure from waning COVID testing demand, product exits, and pricing challenges. The company's investment narrative now hinges on its broad diagnostics portfolio and international expansion offsetting these declining trends.
QuidelOrtho (QDEL) Is Down 7.5% After Cutting 2026 Revenue Outlook Amid Softer COVID Testing Demand
QuidelOrtho (QDEL) recently reported Q2 2026 results, with sales rising to US$630.9 million and a narrowed net loss of US$92.9 million. However, the company cut its full-year 2026 revenue outlook to US$2.52 billion to US$2.60 billion due to softer first-half sales, waning COVID testing demand, product exits, and pricing challenges. This downward revision has led to a 7.5% drop in the stock and reinforces the need for the company to execute on non-COVID growth to offset these headwinds.
Neuberger Berman Group LLC Trims QuidelOrtho Corp (QDEL) Stake -- Shares Trade 59% Below GF Value
Neuberger Berman Group LLC reduced its stake in QuidelOrtho Corp (QDEL) by 4.34% on July 31, 2026, selling shares at $16.77 each. This divestment comes as QuidelOrtho faces significant financial and operational challenges, including a low GF-Score of 45/100 and negative growth trends, despite its shares trading well below their GF Value. The move reflects Neuberger Berman's cautious approach and strategic reallocation of capital towards more promising opportunities, given QuidelOrtho's deteriorating fundamentals in the post-pandemic diagnostics sector.
QuidelOrtho partially recovers from earnings slide, rising 12% (QDEL:NASDAQ)
QuidelOrtho (QDEL) shares rebounded by nearly 12% after a two-session decline triggered by its Q2 earnings release. The company had initially fallen despite beating top and bottom-line estimates due to significant cuts in full-year revenue and EPS guidance and the withdrawal of free cash flow guidance. Risks include reduced demand in China and a softer global respiratory market, though some investors are holding out for a turnaround.
QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered
QuidelOrtho (QDEL) reported second-quarter 2026 adjusted earnings and revenues that surpassed analyst estimates. Despite this beat, the company lowered its full-year 2026 guidance due to persistent weakness in the China market and a more conservative outlook for the upcoming respiratory season, leading to a significant drop in its stock price. The company highlighted growth in Labs and Point of Care businesses but noted challenges in China and negative operating cash flow.
QuidelOrtho Corporation revenue up 3% to USD 631M in Q2 2026
QuidelOrtho Corporation announced its Q2 2026 financial results, reporting a 3% increase in total revenue to $631 million. The company experienced strong growth in its core business and across regions, with the exception of China, where proposed IVD pricing guidelines impacted sales. Consequently, QuidelOrtho has revised its full-year 2026 revenue and earnings guidance.
QuidelOrtho Corporation (QDEL) Stock Positioned for Reweighting Towards Peers Amid Deleveraging
McIntyre Partnerships, an investment company, delivered flat performance in H1 2026, with QuidelOrtho Corporation (QDEL) as its largest holding. Despite volatility, the firm remains confident in QDEL, anticipating potential growth through a proposed sale of its Point-of-Care (POC) division for approximately $1.5 billion. This transaction would deleverage the company, allowing the remaining Ortho business, a historical steady performer, to reweight towards peers as it exits the volatile flu and COVID business.
Sei Investments Co. Buys 57,615 Shares of QuidelOrtho Corporation $QDEL
Sei Investments Co. significantly increased its stake in QuidelOrtho Corporation (NASDAQ:QDEL) by 27.2% in the first quarter, adding 57,615 shares to reach a total of 269,178 shares valued at $4.42 million. Despite this institutional buying and a high institutional ownership of 99%, analyst sentiment remains cautious with an average "Reduce" rating and a consensus price target of $13.62, following the company's recent miss on earnings and revenue estimates. QuidelOrtho's stock performance reflects these challenges, with a negative P/E ratio and a 10.5% year-over-year revenue decline in the last quarter.
QuidelOrtho Corporation Revenue Breakdown – BIVA:QDEL1
This article provides a brief overview of QuidelOrtho Corporation's revenue breakdown. Last year, the company generated 49.22 billion MXN, with its Labs segment contributing the most at 27.14 billion MXN. The United States was the largest regional contributor, accounting for 25.90 billion MXN of the revenue.
QuidelOrtho Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:QDEL) 2026-08-07
QuidelOrtho Corporation (NASDAQ:QDEL) released its Q2 2026 earnings call presentation on August 7, 2026. The company reported an EPS of $0.13, beating estimates by $0.18, and revenue of $630.90M, surpassing expectations by $12.07M, representing a 2.77% year-over-year increase. This presentation was published in conjunction with their earnings call results.
QuidelOrtho (NASDAQ:QDEL) Shares Gap Down - Time to Sell?
QuidelOrtho (NASDAQ:QDEL) shares gapped down significantly, opening at $12.67 after closing at $16.32, and later trading near $11.98. The company reported better-than-expected quarterly earnings, with $0.13 EPS against a forecasted loss of $0.05 and revenue of $630.9 million. Despite this, analysts maintain a cautious "Reduce" rating for the stock, with an average price target of $13.62.
QuidelOrtho stock drops after Q2 results (QDEL:NASDAQ)
QuidelOrtho Corporation (QDEL) stock dropped over 25% following its Q2 2026 earnings report, despite reporting better-than-expected financials. The decline was attributed to the company lowering its full-year outlook, citing significant market headwinds, especially in China. QuidelOrtho's quarterly revenue reached $630.9M, showing approximately 3% year-over-year growth.
QuidelOrtho Q2 Earnings Call Highlights
QuidelOrtho reported a 2% increase in Q2 revenue on a constant-currency basis, reaching $631 million, despite significant headwinds from China and a softer respiratory testing environment. The company lowered its full-year 2026 revenue, adjusted EBITDA, and adjusted EPS forecasts, and withdrew free cash flow guidance due to uncertainties in China, respiratory demand, and working capital. Management emphasized strong underlying business performance outside China and is implementing cost-improvement measures to address challenges.
QuidelOrtho Corp Quarterly Earnings Report
QuidelOrtho Corp (QDEL) has released its unaudited quarterly report for the period ended June 28, 2026, detailing a completed acquisition of LEX Diagnostics for $174.6 million, increased borrowings of $2,891.1 million, and a new equity award of 356,555 restricted stock units to its new CFO. The company is also pursuing an Optimization Plan expected to generate $50 million in net cost savings by 2027, against $100 million in pre-tax charges, and is winding down its SAVANNA Exit and U.S. donor screening portfolio. Total revenues decreased by 4% year-over-year for the six months ended June 28, 2026, primarily due to lower respiratory product sales, the termination of a Joint Business arrangement, and evolving market dynamics in China.
QuidelOrtho (Nasdaq: QDEL) trims 2026 revenue and EPS guidance
QuidelOrtho (Nasdaq: QDEL) has reported its second-quarter 2026 results, showing a 2.8% year-over-year revenue increase to $630.9 million but a GAAP net loss of $92.9 million. The company has trimmed its full-year 2026 financial guidance, reducing expected revenue, adjusted EBITDA, and adjusted EPS, and withdrawing free cash flow guidance due to "demand headwinds in China related to the proposed IVD pricing guidelines and a softer global respiratory environment."
Earnings call transcript: QuidelOrtho beats Q2 2026 estimates but cuts outlook
QuidelOrtho reported stronger-than-expected Q2 2026 adjusted earnings and revenue, driven by strong performance outside of China. However, the company cut its full-year revenue guidance and withdrew free cash flow guidance due to persistent challenges in China and a more cautious outlook for the upcoming respiratory season. Despite the headwinds, management emphasized the underlying strength of its core businesses and its commitment to improving cash conversion and reducing leverage.
Earnings Flash (QDEL) QuidelOrtho Corporation Reports Q2 Revenue $630.9M, vs. FactSet Est of $618.7M
QuidelOrtho Corporation (QDEL) reported its Q2 revenue at $630.9 million, surpassing FactSet's estimate of $618.7 million. This announcement indicates stronger-than-expected financial performance for the company in the second quarter. The article also mentions recent changes in the company's indices and the appointment of a new Principal Financial Officer.
QuidelOrtho (NASDAQ:QDEL) Surprises With Q2 CY2026 Sales But Stock Drops 21.6%
QuidelOrtho (NASDAQ:QDEL) reported better-than-expected revenue and non-GAAP profit for Q2 CY2026, with sales up 2.8% year-on-year to $630.9 million and adjusted EPS of $0.13. Despite beating analyst estimates for the quarter, the company's stock dropped 21.6% due to a significant reduction in its full-year revenue and EPS guidance, largely attributed to demand headwinds in China and a softer global respiratory environment. The diagnostics company, formed from the 2022 merger of Quidel and Ortho Clinical Diagnostics, has struggled with consistent long-term growth and profitability, showing declining sales and operating margins over the past five years.
QuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimates
QuidelOrtho (QDEL) reported strong Q2 results, surpassing Zacks Consensus Estimates for both earnings and revenue. The company posted earnings of $0.13 per share against an expected loss of $0.04 per share, and revenues of $630.9 million, exceeding the $613.9 million estimate. Despite the positive earnings surprise, QDEL shares have underperformed the S&P 500 year-to-date, but the current Zacks Rank #2 (Buy) suggests a potential market outperformance in the near future.
All eyes on Quidel earnings as estimates tumble, asset sale looms
Quidel Corporation is set to report its second-quarter earnings after market close on Thursday, August 6, 2026, with analysts anticipating a loss of 4 cents per share. Investor confidence has waned due to declining EPS estimates and uncertainty surrounding the potential $1.5 billion sale of its point-of-care testing business. Key concerns for investors include the strategic review, impact of China's policy changes on revenue, and growth in non-respiratory diagnostics.
QuidelOrtho Reports Second Quarter 2026 Financial Results
QuidelOrtho Corporation announced its second-quarter 2026 financial results, with total revenue increasing 3% reported and 2% in constant currency, primarily driven by growth in Labs and Point of Care segments. The company updated its full-year 2026 financial guidance downwards due to demand headwinds in China related to proposed IVD pricing guidelines and a softer global respiratory environment. Despite a GAAP net loss of $93 million, adjusted EBITDA improved by 310 basis points, and the company remains focused on strengthening its balance sheet and improving cash conversion.
Quidelortho Corp (QDEL) News, Articles, Events & Latest Updates
This article provides recent news and updates for QuidelOrtho Corp (QDEL), highlighting its strong Q2 2026 earnings and revenue performance, which surpassed analyst estimates. It also includes details about the company's financial results, upcoming earnings reports, and an article discussing the changing landscape of the drug crisis, featuring QuidelOrtho's involvement. Additionally, it mentions QuidelOrtho's stock as a potential addition to portfolios due to its strong product portfolio and cost-saving efforts.
QuidelOrtho (NASDAQ:QDEL) Shares Down 5.7% - What's Next?
QuidelOrtho (NASDAQ:QDEL) shares dropped 5.7% after the company missed quarterly earnings expectations, reporting a $0.04 loss per share against an anticipated $0.37 profit and a 10.5% year-over-year revenue decline. Analysts maintain a cautious stance with a "Reduce" consensus rating and an average price target below its current trading level. Despite institutional investors increasing their holdings, the stock's future performance remains uncertain due to missed financial targets and a negative market sentiment.
Earnings Preview: QuidelOrtho to Report Financial Results Post-market on August 06
This article announces that QuidelOrtho (QDEL) is scheduled to release its financial results on August 6, 2026, after the market closes. The company will also host a conference call and webcast on the same day to discuss the results. The release includes information on how to access the webcast and replay.
Quidelortho Corporation (QDEL1) Q3 2022 Earnings Report - Results, Call & Slides
Quidelortho Corporation (QDEL1) reported strong Q3 2022 earnings, significantly beating analyst expectations with an actual EPS of $32.39 against a consensus of $12.97. The company's actual revenue reached $13.72 billion, surpassing the expected $12.60 billion, marking a 53.77% year-over-year growth. The report includes details on past and upcoming earnings dates, offering a comprehensive overview of the financial performance.
QuidelOrtho Corporation Revenue Breakdown – NASDAQ:QDEL
QuidelOrtho Corporation (NASDAQ: QDEL) generated a total revenue of $2.73 billion USD last year. The "Labs" segment was the top-performing segment, contributing $1.51 billion USD. Geographically, the United States was the largest contributor to revenue, accounting for $1.44 billion USD.
Quidelortho Corporation (QDEL1) Q1 2023 Earnings Report - Results, Call & Slides
QuidelOrtho Corporation (QDEL1) announced its Q1 2023 earnings, reporting actual EPS of $31.52, which beat the consensus of $26.14 by $5.38. The company also surpassed revenue expectations, achieving $14.80 billion against an expected $13.62 billion. The report includes details on the earnings call, an audio recording, and a slide deck, with the next earnings date estimated for August 6, 2026.
Quidelortho Corporation (QDEL1) Q2 2023 Earnings Report - Results, Call & Slides
QuidelOrtho (MX:QDEL1) reported its Q2 2023 earnings, missing consensus EPS expectations with an actual EPS of $4.55 against a consensus of $4.88. However, the company beat revenue expectations, reporting $11.61 billion against an expected $10.77 billion, marking an 8.13% year-over-year revenue growth. The next estimated earnings date for QuidelOrtho is August 6, 2026.
QuidelOrtho to Report Second Quarter 2026 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) announced it will release its financial results for the second quarter of 2026 on Thursday, August 6, 2026, after the market closes. Following the release, the company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results, with access and presentation materials available on its investor relations website. QuidelOrtho, a global diagnostic solutions provider, is dedicated to advancing diagnostics for improved patient outcomes.
Quidelortho Corporation (QDEL1) Q2 2024 Earnings Report - Results, Call & Slides
Quidelortho Corporation (QDEL1) has released its Q2 2024 earnings report, showing an actual EPS of -$1.23, significantly beating the consensus EPS of -$4.08. The company's actual revenue was $11.14 billion, surpassing the expected $10.74 billion. The earnings call took place on July 31, 2024, and the next earnings report is estimated for July 30, 2026.
Quidelortho Corporation (QDEL1) Q2 2025 Earnings Report - Results, Call & Slides
QuidelOrtho Corporation (QDEL1) has released its Q2 2025 earnings report, significantly beating both EPS and revenue expectations. The company reported an actual EPS of $2.10 against a consensus of $0.04 and actual revenue of $10.77 billion against an expected $10.70 billion. The Q2 2025 earnings call took place on August 5, 2025, and the next earnings report is estimated for July 30, 2026.
QuidelOrtho to Report Second Quarter 2026 Financial Results
QuidelOrtho Corporation announced it will report its Q2 2026 financial results after market close on Thursday, August 6, 2026. A conference call will follow at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results, with access and presentation materials available on the company's investor relations website, along with a replay.
QuidelOrtho Results Will Arrive After Market Close Aug. 6
QuidelOrtho (Nasdaq: QDEL) announced it will report its Q2 2026 financial results after market close on Thursday, August 6, 2026. A conference call will follow at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results, which will be accessible via the "Events & Presentations" section of the company's Investor Relations website. Historically, a previous earnings-date announcement for QDEL was followed by a -10.11% 24-hour stock move.
Quidelortho Corporation (QDEL1) Q3 2025 Earnings Report - Results, Call & Slides
Quidelortho Corporation (QDEL1) reported its Q3 2025 earnings, surpassing analyst expectations with an actual EPS of $14.01 against a consensus of $9.02, and actual revenue of $12.26 billion compared to an expected $11.72 billion. Despite beating estimates, the company experienced a year-over-year revenue growth decline of 3.66%. The earnings announcement was made on November 5, 2025, with the next estimated earnings date set for July 30, 2026.
Beyond Fentanyl: How the Drug Crisis Is Changing
QuidelOrtho Corporation has released a new episode of its Science Bytes podcast discussing the evolving drug overdose landscape, focusing on polysubstance use, counterfeit medications, and emerging synthetic opioids like nitazenes. The episode highlights a decline in U.S. overdose deaths in 2025 but stresses the continued complexity of toxicology testing and the critical role laboratories play in patient care. It emphasizes ongoing challenges for clinicians due to the unpredictable illicit drug supply and the need for collaboration across healthcare.
QuidelOrtho Corporation Actuals & Estimates (NASDAQ:QDEL)
This article provides an in-depth financial overview of QuidelOrtho Corporation (NASDAQ:QDEL), including its current stock price, historical performance, and analyst forecasts. It details the company's financials such as earnings, revenue, net income, and market capitalization, along with upcoming earnings release dates. The article also covers QuidelOrtho's stock volatility, employee count, and EBITDA, offering insights for potential investors.
Reasons to Add QuidelOrtho Stock in Your Portfolio for Now
QuidelOrtho Corporation (QDEL) is considered a good investment due to its robust product portfolio, ongoing cost-saving initiatives, and positive performance in its Labs and Immunohematology segments despite mixed Q1 2026 results. However, the company faces risks from its overreliance on the respiratory segment, which significantly impacts its revenues and profitability. The article suggests QDEL could grow but highlights the volatility associated with its respiratory testing business.
Beyond Fentanyl: How the Drug Crisis Is Changing
QuidelOrtho Corporation's Science Bytes podcast recently released an episode discussing the evolving drug overdose landscape, focusing on new guidance from the Association for Diagnostics and Laboratory Medicine (ADLM). The episode highlights a decline in overdose deaths but underscores ongoing challenges, including counterfeit medications, polysubstance use, and emerging synthetic opioids like nitazenes. It emphasizes the critical role of laboratories and collaboration between labs and emergency departments in addressing the complex drug crisis.
QuidelOrtho Corp (QDEL) Shares Fall 4.5% -- What GF Score of 43 Tells Investors
QuidelOrtho Corp (QDEL) saw its shares fall 4.5% to $16.58. GuruFocus analysis indicates the stock is undervalued by 55.6% according to its GF Value of $37.36, but it carries a "Possible Value Trap" warning due to its low GF Score of 43/100, weak financial strength (3/10), and poor momentum (1/10). No insider transactions were reported in the last three months, suggesting caution may be warranted despite the apparent undervaluation.
QuidelOrtho Corp (QDEL) Shares Fall 4.5% -- What GF Score of 43 Tells Investors
QuidelOrtho Corp (QDEL) saw its shares fall 4.5% on July 20, 2026, closing at $16.58. While GuruFocus's GF Value™ indicates the stock is undervalued by 55.6% at $37.36, its GF Score™ of 43/100 suggests caution due to low financial strength and momentum, and average profitability. The article also notes the absence of insider transactions over the last three months, which could imply a lack of insider confidence or a wait-and-see approach.
Zacks Industry Outlook Highlights Terumo, QuidelOrtho, Lumexa Imaging and Brainsway
Zacks Equity Research identifies Terumo, QuidelOrtho, Lumexa Imaging Holdings, Inc., and Brainsway as medical product stocks poised for success despite industry headwinds such as inflation, supply-chain issues, and tariffs. The medical products industry is characterized by continuous innovation, a shift to ambulatory and home-based care, and accelerating advancements in robotics and specialty therapeutics. Despite challenges, these four companies are employing pricing actions, cost control, and innovative pipelines to navigate the complex market.
QuidelOrtho (QDEL) 7th Annual Evercore ISI HealthCONx Conference Summary
QuidelOrtho (QDEL) discussed its business performance, segment trends, product dynamics, and financial outlook at the 7th Annual Evercore ISI HealthCONx Conference. The company detailed growth in its Labs and Immunohematology businesses, the winding down of U.S. Donor Screening, and stabilizing respiratory revenue. QuidelOrtho also outlined targets for cost savings, adjusted EBITDA margins, EPS growth, and leverage ratio improvement.
Quidelortho Corporation (QL1A) Q2 2024 Earnings Report - Results, Call & Slides
Quidelortho Corporation (QL1A) released its Q2 2024 earnings report, beating both EPS and revenue expectations. The company reported an actual EPS of -CHF0.06 against a consensus of -CHF0.19, and actual revenue of CHF514.07M compared to an expected CHF495.66M. The earnings call took place on July 31, 2024, after market close, and the next earnings report is estimated for July 30, 2026.
